Archive — US — techcrunch
Max Hodak’s Science Corp. is preparing to place its first sensor in a humanbrain
Max Hodak's startup, Science Corp., is set to initiate U.S. human trials for a biohybrid brain-computer interface, led by Yale neurobiologist Dr. Murat Günel. The first sensor will be implanted in patient's brains to create a link between lab-grown neurons and electronics. Funded with $230M, Science aims to revolutionize neurological treatment and enhance human capabilities, planning to test the device on patients needing significant brain surgery.
Key points
- Science Corp. was founded in 2021 by Max Hodak, former Neuralink president.
- Dr. Murat Günel from Yale Medical School joins as a scientific adviser after two years of discussions.
- The company has raised $230 million, valuing at $1.5 billion, to develop a biohybrid brain-computer interface.
- The first sensor aims to create a bridge between electronics and lab-grown neurons, addressing limitations of traditional metal probes.
- Initial testing will focus on patients undergoing significant brain surgery.
- Potential applications include treatments for neurological conditions like Parkinson's disease and monitoring brain tumor activity.
Why it matters
- The news highlights a significant trend in biotechnology concerning human brain-computer interfaces.
- Neuralink and similar organizations are paving the way for advanced neurological therapies.
- 2025 IT trends emphasize the integration of AI and bioengineering, with a focus on ethical implications in medical technologies.
Science Corp. represents a promising leap in neurotechnology, with its innovative approach to brain-computer interfaces aiming for significant advancements in medical treatments while addressing ethical questions surrounding human enhancement.